Contact
Please use this form to send email to PR contact of this press release:
THE UNIVERSITY OF COLORADO CONCLUDES SEMAPHORIN 7A IN VIVO STUDY WITH GLOBAL CANCER TECHNOLOGY’S DRUG, GCT-007
TO:
John Clark
Individual
+1 619-818-2411